Showing 1891-1900 of 6037 results for "".
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- Lexitas Announces George N. Magrath, MD, MBA Assumes Role of Chief Executive Officerhttps://modernod.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/George N. Magrath, MD, MBA, MS, has been named CEO of Lexitas Pharma Services. Chad Ice will transition from the role as CEO to President with a focus on strategic growth initiatives as well as the expansion of the Lexitas Board of Directors. These changes became effective February 1, 2021. <
- Azar Expects 40M COVID-19 Vaccine Doses Ready to Distribute By End of Decemberhttps://modernod.com/news/azar-expects-40m-covid-19-vaccine-doses-ready-to-distribute-by-end-of-december/2478576/Department of Health and Human Services Secretary Alex Azar expects 40 million doses of Pfizer and Moderna’s COVID-19 vaccines will be ready for distribution by the end of December as providers must gear up now to allocate the doses, according to a FierceHealthcare
- BVI Launches CryoTreq for Treatment of Retinal Tears and Detachmentshttps://modernod.com/news/bvi-launches-cryotreq-for-treatment-of-retinal-tears-and-detachments/2477863/BVI announced the European launch of CryoTreq—a single-use, handheld cryosurgery device for ophthalmology. The device functions without external connections to equipment, gas tanks, or power and does not require any service or maintenance. CryoTreq enables a minimally invasive ab externo a
- 1-800 Contacts Launches Online Glasses Lens Replacement Brand, Boomerang Lenseshttps://modernod.com/news/covid-19-weekly-review/2477734/1-800 Contacts unveiled Boomerang, an online lens replacement service that provides new lenses for consumers to put in their current glasses without having to visit an eye doctor or optical shop. As the current health crisis began to unfold, and eyecare providers and optical shops began f
- FDA Launches Program to Speed Development of COVID-19 Treatmentshttps://modernod.com/news/fda-launches-program-to-speed-development-of-covid-19-treatments/2477511/The FDA unveiled a new initiative, dubbed the “Coronavirus Treatment Acceleration Programme (CTAP),” designed to expedite the development of effective treatments for patients with COVID-19. Alex Azar, secretary of the US Department of Health and Human Services, said that “as par
- Avellino Expands Production of Genetic Test Kits for Coronavirus Detectionhttps://modernod.com/news/avellino-expands-production-of-genetic-test-kits-for-coronavirus-detection/2477415/Avellino announced that it is adding additional production shifts for its newly developed coronavirus diagnostic, the Avellino SARS-CoV-2/COVID-19 test. The AvellinoCoV2 ultra-rapid genetic test is in increasing demand by health systems, public health services, and first-responders because of its
- President Invokes the Defense Production Act in Response to COVID-19https://modernod.com/news/president-invokes-the-defense-production-act-in-response-to-covid-19/2477413/The President and the Secretary of Health and Human Services (HHS) reportedly plan to invoke the Defense Production Act of 1950 (DPA) to support the COVID-19 response by giving the federal government priority over all other customers for items such as masks and ventilators, according to an Arnold
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will
- Retina Specialist Brett Foxman, MD, Earns U.S. Patent for Scleral Depressorhttps://modernod.com/news/retina-specialist-brett-foxman-md-earns-u-s-patent-for-scleral-depressor/2476788/Brett Foxman, MD, Clinical Service Chief in Ophthalmology at Shore Medical Center in Somers Point, New Jersey, recently won a U.S. patent for his new version of the scleral depressor. Dr. Foxman said after performing thousands of eye surgeries using a tool that had stayed essentially uncha